Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Inpatient Dermatology: Finding Solutions to Challenging Cases

Description

The presentation by Dr. Anna Cogan focused on challenging inpatient dermatology cases, particularly highlighting the nuances between conditions like hemophagocytic lymphohistiocytosis (HLH) and drug reaction with eosinophilia and systemic symptoms (DRESS). The first case involved a 55-year-old with complex medical issues stemming from chronic myeloid leukemia who developed a rash that raised concerns for HLH or DRESS. Through a comprehensive analysis of clinical symptoms, laboratory results, and response to treatment, the case underscored the importance of correctly identifying or ruling out underlying conditions. The second case detailed an 18-year-old who experienced complications related to having HLH and a subcutaneous panniculitis-like T-cell lymphoma after receiving vaccinations. This case emphasized the need for differential diagnosis using HLH criteria and the challenges of treatment protocols. The final case involved a 37-year-old post-cardiac surgery patient who developed purpura fulminans, connecting it to transient disseminated intravascular coagulation (DIC) and demonstrating the complexities in expected treatments. Dr. Cogan concluded that while conducting inpatient dermatology, understanding the trajectory of illnesses and timely identification of etiological factors is crucial for effective management.

View more

Conclusions

  • Differentiating between DRESS and HLH can be challenging, requiring careful diagnosis and treatment.
  • HLH can manifest from both primary genetic conditions and secondary triggers, such as medications or infections.
  • It is critical to identify underlying causes when diagnosing HLH, as treatment differs significantly between HLH disease and HLH mimics.
  • The use of specific diagnostic criteria is necessary to properly identify patients with HLH.
  • Corticosteroids are a primary treatment for HLH, especially when associated with underlying conditions like DRESS or SPTCL.
  • Early treatment of underlying conditions can lead to better patient outcomes in cases of HLH.
  • Pediatr Blood Cancer. 2019 Nov;66(11)
  • Pediatr Blood Cancer. 2007 Feb;48(2):124-31.
  • Hematology Am Soc Hematol Educ Program. 2009;127-31.
  • Cancer. 2004;101:1404-1413.
  • JAAD Case Rep. 2022 Oct;28:18-20.
  • Clin Case Rep. 2023 Apr 5;11(4):e7143.